封面
市场调查报告书
商品编码
1634188

全球脸部注射剂市场 - 2025 - 2033

Global Facial Injectables Market - 2025 - 2033

出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年,全球脸部注射市场达到131.4亿美元,预计到2032年将达到276.4亿美元,2025-2032年预测期间复合年增长率为9.4%。

全球脸部注射剂市场是医疗美容行业的一部分,专注于涉及注射真皮填充剂和神经毒素等物质的非手术治疗。这些注射主要用于脸部年轻化、透过减少皱纹、恢復流失的体积和改善整体皮肤纹理来增强美观。

脸部注射剂的类型包括真皮填充剂和神经毒素。真皮填充剂是一种注入皮下的凝胶状物质,可增加体积、抚平皱纹并增强脸部轮廓。常见类型包括透明质酸填充剂和羟基磷灰石钙填充剂。这类神经毒素包括 A 型肉毒毒素(例如 BOTOX)等产品,它会暂时麻痹肌肉,以抚平由脸部表情引起的动态皱纹。

脸部注射剂的主要用途是改善美容外观,特别是前额、眼睛周围(鱼尾纹)和嘴巴等区域。一些注射剂也用于治疗疾病,包括出汗过多和偏头痛。这些因素推动了全球脸部注射剂市场的扩张。

市场动态:

驱动程式和限制

对非手术程序的需求不断增长

对非手术程序的需求不断增长,极大地推动了全球面部注射剂市场的成长,预计将在整个市场预测期内推动成长。

许多消费者越来越多地选择注射剂等非手术选择,因为与传统手术相比,它们可以提供有效的结果,且停机时间最短。这种偏好与对适应忙碌生活方式的快速、方便的治疗的渴望是一致的。注射配方和技术的创新提高了这些治疗的安全性、有效性和舒适性。新技术可以实现更精确的应用和更持久的效果,使非手术选择对消费者更具吸引力。

社群媒体的兴起提高了人们对美容疗程的认识,导致人们对保持年轻外表的兴趣增加。有影响力的人和名人经常分享他们的非手术治疗经验,使这些治疗正常化并鼓励其他人考虑它们。对非手术程序的需求不断增长极大地影响了全球脸部注射剂市场的成长。随着消费者不断寻求有效、便利和微创的解决方案来改善外表,这一趋势预计将推动脸部注射剂市场的进一步创新和扩张。

此外,该行业的主要参与者推出了创新产品,这将推动脸部注射市场的成长。例如,2023 年 8 月,艾尔建 (Allergan) 推出了最新的脸部填充剂 Juvederm Volux。 Juvederm 系列的这款新产品是一种基于透明质酸的真皮填充剂,可恢復失去的脸部体积。 Volux 与前辈的不同之处在于其独特的一致性,专为增强脸部轮廓效果而设计。

Juvederm Volux 旨在改善下巴和下颚线的轮廓,提供更具雕塑感的外观。它采用艾尔建 (Allergan) 的专利 VYCROSS 技术,可实现更光滑的凝胶配方,与皮肤完美融合。这种填充剂的效果可以持续 18 至 24 个月,对于那些寻求这些领域美观增强的人来说,它是一个持久的选择。

此外,修丽可 (SkinCeuticals) 于 2024 年 7 月推出了 P-TIOX,这是一种经过临床支持的胜肽血清,旨在减少表情皱纹的出现,从神经毒素注射的效果中汲取灵感。这种创新血清旨在复製和增强通常透过注射治疗获得的效果,为寻求抗衰老益处的人提供非侵入性替代方案。所有这些因素都对全球脸部注射市场提出了需求。

此外,对数位工具整合成长的需求不断增长,有助于全球脸部注射市场的扩张。

不良影响和安全问题

不良反应和安全问题严重限制了全球脸部注射剂市场。虽然这些产品被广泛用于美容,但潜在的副作用和安全问题可能会阻止消费者寻求治疗。

许多患者在註射治疗后会出现暂时的副作用,包括注射部位肿胀、瘀青、发红和疼痛。这些反应通常很轻微,并会在几天到几週内消失。然而,它们的出现可能会导致不满,特别是对于那些寻求立即美学改善的人来说。

虽然不太常见,但脸部注射可能会引起更严重的併发症,包括感染、血管阻塞和肉芽肿。有些不良反应可能不会立即显现,可能在治疗后数週或数月发生。例如,迟髮型超敏反应或慢性发炎可能会因引入体内的异物而发生。虽然罕见,但对注射剂成分的过敏反应可能会发生,并可能导致敏感个体出现过敏反应等严重后果。因此,上述因素可能限制全球脸部注射剂市场的潜在成长。

目录

第 1 章:方法与范围

第 2 章:定义与概述

第 3 章:执行摘要

第 4 章:动力学

  • 影响因素
    • 司机
      • 对非手术程序的需求不断增长
    • 限制
      • 不良影响和安全问题
    • 机会
    • 影响分析

第 5 章:产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 专利分析
  • 监管分析
  • SWOT分析
  • 未满足的需求

第 6 章:依产品类型

  • 真皮填充剂
    • 透明质酸填充剂 (HA)
    • 羟基磷灰石钙 (CaHA)
    • 聚左旋乳酸
    • 胶原蛋白注射剂
    • 脂肪注射
    • 聚甲基丙烯酸甲酯微球(PMMA)
  • 神经毒素
    • A 型肉毒桿菌素(Botox)
    • 运动障碍
    • 西奥明

第 7 章:按申请

  • 脸部线条矫正
  • 丰唇手术
  • 脸部提升
  • 痤疮疤痕治疗
  • 脂肪萎缩治疗
  • 其他的

第 8 章:最终用户

  • 医院
  • 皮肤科诊所
  • 医疗水疗中心
  • 其他的

第 9 章:按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章:竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章:公司简介

  • AbbVie.
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Galderma
  • Merz Pharma
  • REVANCE AESTHETICS.
  • Sinclair
  • Ipsen Pharma.
  • Medytox.
  • HUGEL.
  • Suneva Medical, Inc. (Tiger Aesthetics Medical, LLC.)
  • Prollenium Medical Technologies.

第 12 章:附录

简介目录
Product Code: PH8998

The global facial injectables market reached US$ 13.14 billion in 2024 and is expected to reach US$ 27.64 billion by 2032, growing at a CAGR of 9.4 % during the forecast period 2025-2032.

The global facial injectables market is a segment of the medical aesthetics industry that focuses on non-surgical treatments involving the injection of substances like dermal fillers and neurotoxins. These injectables are primarily used for facial rejuvenation, enhancing aesthetics by reducing wrinkles, restoring lost volume, and improving overall skin texture.

Types of facial injectables include dermal fillers and neurotoxins. Dermal fillers are gel-like substances injected beneath the skin to add volume, smooth out wrinkles, and enhance facial contours. Common types include hyaluronic acid fillers and calcium hydroxylapatite fillers. Neurotoxins in this category include products such as botulinum toxin type A (e.g., BOTOX), which temporarily paralyze muscles to smooth out dynamic wrinkles caused by facial expressions.

The primary use of facial injectables is to improve cosmetic appearance, particularly in areas such as the forehead, around the eyes (crow's feet), and the mouth. Some injectables are also employed for medical conditions, including excessive sweating and migraines. These factors have driven the global facial injectables market expansion.

Market Dynamics: Drivers & Restraints

Growing Demand for Non-Surgical Procedures

The growing demand for non-surgical procedures is significantly driving the growth of the global facial injectables market and is expected to drive throughout the market forecast period.

Many consumers are increasingly opting for non-surgical options like injectables because they offer effective results with minimal downtime compared to traditional surgical procedures. This preference aligns with a desire for quick and convenient treatments that fit into busy lifestyles. Innovations in injectable formulations and techniques have enhanced the safety, efficacy, and comfort of these treatments. New technologies allow for more precise applications and longer-lasting results, making non-surgical options more appealing to consumers.

The rise of social media has heightened awareness of aesthetic treatments, leading to increased interest in maintaining a youthful appearance. Influencers and celebrities often share their experiences with non-surgical procedures, normalizing these treatments and encouraging others to consider them. The increasing demand for non-surgical procedures significantly impacts the growth of the global facial injectables market. As consumers continue to seek effective, convenient, and minimally invasive solutions for enhancing their appearance, this trend is expected to drive further innovations and expansions within the facial injectables market.

Furthermore, key players in the industry have innovative product launches that would drive this facial injectable market growth. For instance, in August 2023, Allergan introduced its latest facial filler, Juvederm Volux. This new addition to the Juvederm line is a hyaluronic acid-based dermal filler to restore lost facial volume. What sets Volux apart from its predecessors is its unique consistency, specifically engineered for enhanced performance in facial contouring.

Juvederm Volux is designed to improve the definition of the chin and jawline, providing a more sculpted appearance. It utilizes Allergan's patented VYCROSS technology, which allows for a smoother gel formulation that integrates well with the skin. This filler's effects can last 18 to 24 months, making it a long-lasting option for those seeking aesthetic enhancements in these areas.

Also, in July 2024, SkinCeuticals launched P-TIOX, a clinically backed peptide serum designed to reduce the appearance of expression wrinkles, drawing inspiration from the effects of neurotoxin injections. This innovative serum aims to replicate and enhance the results typically achieved through injectable treatments, providing a non-invasive alternative for those seeking anti-aging benefits. All these factors demand the global facial injectables market.

Moreover, the rising demand for the growth of integration of digital tools contributes to the global facial injectables market expansion.

Adverse Effects and Safety Concerns

Adverse effects and safety concerns present significant restraints in the global facial injectables market. While these products are widely utilized for aesthetic enhancement, potential side effects and safety issues can deter consumers from pursuing treatment.

Many patients experience temporary side effects following injectable treatments, including swelling, bruising, redness, and pain at the injection site. These reactions are generally mild and resolve within a few days to weeks. However, their occurrence can lead to dissatisfaction, particularly for those seeking immediate aesthetic improvements.

Although less common, more severe complications can arise from facial injectables, including infection, vascular occlusion, and granulomas. Some adverse reactions may not manifest immediately and can occur weeks or months after treatment. For example, delayed hypersensitivity reactions or chronic inflammation may develop in response to the foreign material introduced into the body. While rare, allergic responses to the components of injectables can occur and may lead to severe outcomes such as anaphylaxis in sensitive individuals. Thus, the above factors could be limiting the global facial injectables market's potential growth.

Segment Analysis

The global facial injectables market is segmented based on product type, application, end-user, and region.

Product Type:

The botulinum toxin type A (Botox) segment is expected to dominate the global facial injectables market share

The botulinum toxin type A (Botox) segment holds a major portion of the global facial injectables market share and is expected to continue to hold a significant portion of the global facial injectables market share during the forecast period.

The botulinum toxin type A (Botox) segment is a crucial component of the global facial injectables market, significantly contributing to its growth and popularity. Botulinum toxin type A, commonly referred to as Botox, is a neurotoxin produced by the bacterium Clostridium botulinum. It is primarily utilized in aesthetic medicine to temporarily paralyze specific facial muscles, effectively reducing the appearance of dynamic wrinkles caused by facial expressions.

The main areas treated with Botox include forehead lines, frown lines (glabellar lines), and crow's feet (lines around the eyes). There is a notable increase in consumer interest in aesthetic procedures, particularly among younger demographics who are increasingly seeking preventive treatments. The popularity of Botox as a non-invasive option for wrinkle reduction has played a significant role in its market dominance.

Botox treatments are minimally invasive, requiring little to no downtime, which appeals to consumers looking for quick and effective solutions for facial rejuvenation. This convenience factor has led to higher uptake rates for these treatments. Furthermore, key players in the industry have innovative product launches that would drive this facial injectable market growth. For instance, in September 2024, Allergan Aesthetics announced the launch of BOTOX Cosmetic (onabotulinumtoxinA) for the treatment of masseter muscle prominence (MMP) in China.

This approval by the China National Medical Product Administration (NMPA) marks BOTOX as the first neurotoxin authorized for this indication, addressing a common aesthetic concern where an enlarged masseter muscle can lead to a wider, square jawline. The treatment is designed for adults experiencing marked to very marked MMP and offers a temporary improvement in facial appearance. These factors have solidified the segment's position in the global facial injectables market.

Geographical Analysis

North America is expected to hold a significant position in the global facial injectables market share

North America holds a substantial position in the global facial injectables market and is expected to hold most of the market share.

There is a notable shift towards non-invasive cosmetic treatments, such as facial injectables, as consumers seek effective solutions to enhance their appearance without the risks and recovery times associated with surgical options. This trend is particularly strong among younger demographics who are interested in preventive treatments to maintain a youthful look. As disposable incomes rise, especially in emerging markets, more individuals are willing to invest in aesthetic enhancements. This financial capability allows consumers to prioritize cosmetic procedures, significantly contributing to the overall growth of the facial injectables market.

Innovations in injectable formulations and techniques have improved safety, efficacy, and the longevity of results. New products that provide longer-lasting effects and more natural appearances are attracting a broader consumer base, further driving facial injectables market growth. Beyond cosmetic uses, botulinum toxin type A (Botox) and dermal fillers are increasingly utilized for various medical conditions, including chronic migraines, excessive sweating (hyperhidrosis), and muscle spasms. This versatility enhances their market presence and contributes to overall growth.

The stigma surrounding cosmetic procedures has diminished significantly, leading to greater acceptance of facial injectables among diverse demographics, including men. This cultural shift is expanding the consumer base and increasing demand for these treatments. Social media platforms play a crucial role in promoting aesthetic treatments like Botox and dermal fillers. Influencers and celebrities sharing their experiences with these procedures have normalized cosmetic enhancements, encouraging more individuals to consider them.

Furthermore, key players in the industry have innovative product launches and approvals that would drive this facial injectable market growth. For instance, in July 2024, Merz Aesthetics announced that the U.S. Food and Drug Administration (FDA) has approved XEOMIN (incobotulinumtoxinA) as the first and only neurotoxin for the simultaneous treatment of upper facial lines, including forehead lines, frown lines, and crow's feet. This new approval expands XEOMIN's indications beyond its initial 2011 approval for treating moderate to severe glabellar lines (frown lines).

Also, in March 2023, in Dallas, Galderma unveiled FACE by Galderma, an innovative aesthetic visualization tool that utilizes augmented reality (AR) to help aesthetic professionals and patients visualize the results of injectable treatments before they commence. This cutting-edge application offers a simulated real-time "before and after" view, allowing patients to see what may be achievable through a personalized treatment plan, thereby addressing concerns about the outcomes of injectable procedures.

Thus, the above factors are consolidating the region's position as a dominant force in the global facial injectables market.

Asia Pacific is growing at the fastest pace in the global facial injectables market share

Asia Pacific holds the fastest pace in the global facial injectables market and is expected to hold most of the market share.

The Asia Pacific facial injectables market is set for significant growth, driven by a variety of key factors. A notable rise in disposable incomes across many Asian nations is enabling consumers to invest more in aesthetic enhancements. As financial resources grow, individuals are increasingly prioritizing cosmetic procedures, which significantly contributes to the growth of the facial injectables market.

There is a growing fascination with both cosmetic surgery and non-surgical aesthetic treatments among consumers in the Asia Pacific region. This interest is particularly strong among millennials and younger demographics who are seeking effective solutions to enhance their appearance. Innovations in injectable formulations and techniques have improved safety, efficacy, and the longevity of results. New products that offer longer-lasting effects and more natural appearances are attracting a broader consumer base, further driving market growth.

Furthermore, key players in the industry product launches that would propel this facial injectables market growth in the region. For instance, in May 2024, Galderma launched its hyaluronic acid injectable filler, Restylane VOLYME, in China, alongside the complementary Shape Up Holistic Individualized Treatment (HIT). This innovative filler is specifically designed to address mid-face aging concerns caused by the loss of structural support, reflecting Galderma's dedication to meeting the needs of both patients and injectors in the region. The introduction of these targeted solutions comes at a time when China's aesthetic medicine market has been rapidly expanding, outpacing global growth rates.

Also, in August 2022, Allergan Aesthetics launched Juvederm VOLUX in India, an injectable implant specifically designed to restore and create facial volume. This product is formulated with 25 mg of hyaluronic acid and 3 mg of lidocaine hydrochloride, making it effective for enhancing the chin and jawline areas. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global facial injectables market.

Competitive Landscape

The major global players in the facial injectables market include AbbVie., Galderma, Merz Pharma, REVANCE AESTHETICS., Sinclair, Ipsen Pharma., Medytox., HUGEL., Suneva Medical, Inc. (Tiger Aesthetics Medical, LLC.), and Prollenium Medical Technologies. Among others.

Key Developments

  • In September 2024, Obagi Medical, launched two revolutionary skincare products: ELASTIDERM Lift Up & Sculpt Facial Moisturizer and ELASTIDERM(R) Advanced Filler Concentrate. These new offerings promise transformative results by utilizing cutting-edge technology and advanced formulations to improve skin appearance and texture.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-world Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global facial injectables market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Material
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Demand for Non-Surgical Procedures
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse Effects and Safety Concerns
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Dermal Fillers*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Hyaluronic Acid Fillers (HA)
    • 6.2.4. Calcium Hydroxylapatite (CaHA)
    • 6.2.5. Poly-L-lactic Acid
    • 6.2.6. Collagen Injectables
    • 6.2.7. Fat Injection
    • 6.2.8. Polymethyl Methacrylate Microspheres (PMMA)
  • 6.3. Neurotoxins
    • 6.3.1. Botulinum Toxin Type A (Botox)
    • 6.3.2. Dysport
    • 6.3.3. Xeomin

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Facial Line Correction*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Lip Augmentation
  • 7.4. Face Lift
  • 7.5. Acne Scar Treatment
  • 7.6. Lipoatrophy Treatment
  • 7.7. Others

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Dermatology Clinics
  • 8.4. MedSpas
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. AbbVie. *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Galderma
  • 11.3. Merz Pharma
  • 11.4. REVANCE AESTHETICS.
  • 11.5. Sinclair
  • 11.6. Ipsen Pharma.
  • 11.7. Medytox.
  • 11.8. HUGEL.
  • 11.9. Suneva Medical, Inc. (Tiger Aesthetics Medical, LLC.)
  • 11.10. Prollenium Medical Technologies.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us